BioHarvest Sciences Inc. Share Price Canadian Securities Exchange

Equities

BHSC

CA13767B1013

Food Processing

Delayed Canadian Securities Exchange 15:24:58 05/10/2021 BST 5-day change 1st Jan Change
0.35 CAD +6.06% Intraday chart for BioHarvest Sciences Inc. -2.94% +46.67%

Financials

Sales 2021 2.1M 2.87M 168M Sales 2022 5.5M 7.52M 440M Capitalization 98.54M 135M 7.89B
Net income 2021 -9M -12.3M -720M Net income 2022 -11M -15.04M -881M EV / Sales 2021 77.8 x
Net cash position 2021 1.46M 1.99M 117M Net Debt 2022 8.82M 12.06M 706M EV / Sales 2022 19.5 x
P/E ratio 2021
-16.1 x
P/E ratio 2022
-8.7 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 71.77%
More Fundamentals * Assessed data
Dynamic Chart
BioHarvest Sciences Inc. Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity CI
BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules MT
BioHarvest Sciences Inc. Announces Launch of New Contract Development and Manufacturing Organization Business Unit CI
BioHarvest Sciences Inc. Signs First Contracts with Two Industrial Customers to Develop Complex Molecules Via Its Newly Launched Botanical Synthesis CDMO Business Unit CI
BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding CI
Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products CI
BioHarvest Sciences Inc. Provides Revenue Guidance for the Fourth Quarter 2023 CI
Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023 CI
BioHarvest Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding CI
BioHarvest Sciences Inc. Receives Canadian Product License from Health Canada's Natural and Non-Prescription Health Products Directorate CI
BioHarvest Sciences Inc. Provides Revenue Guidance for the Third Quarter of 2023 CI
BioHarvest Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioHarvest Sciences Up After Reporting Closing of Private Placement of Convertible Notes MT
BioHarvest Sciences Inc. announced that it has received CAD 4.642076 million in funding CI
More news
Managers TitleAgeSince
Chief Executive Officer - 08/06/20
Director of Finance/CFO 72 08/10/18
Chairman 66 26/09/18
Members of the board TitleAgeSince
Director/Board Member 57 18/04/13
Chairman 66 26/09/18
Director/Board Member 73 20/10/21
More insiders
BioHarvest Sciences Inc. is a Canada-based biotechnology company. The Company offers Botanical Synthesis, its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. The Company is leveraging its Botanical Synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. The Company operates through two segments: Nutraceuticals and Pharmaceuticals. The Company offers a polyphenol/antioxidant superfruit product called VINIA, which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine.
Calendar
More about the company